Carnegie Capital Asset Management LLC Buys 3,893 Shares of Amgen Inc. (NASDAQ:AMGN)

Carnegie Capital Asset Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,053 shares of the medical research company's stock after acquiring an additional 3,893 shares during the period. Amgen accounts for about 0.9% of Carnegie Capital Asset Management LLC's holdings, making the stock its 28th biggest position. Carnegie Capital Asset Management LLC's holdings in Amgen were worth $25,073,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Moneta Group Investment Advisors LLC grew its position in Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company's stock valued at $1,980,571,000 after buying an additional 7,532,031 shares during the last quarter. Norges Bank acquired a new stake in Amgen in the fourth quarter valued at $1,351,778,000. Price T Rowe Associates Inc. MD lifted its holdings in Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company's stock valued at $774,791,000 after acquiring an additional 1,806,456 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Amgen during the 4th quarter worth $4,589,900,000. Finally, Morgan Stanley raised its stake in shares of Amgen by 12.9% during the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company's stock worth $3,493,471,000 after buying an additional 1,523,665 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMGN has been the subject of several analyst reports. Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 7th. StockNews.com downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research note on Thursday, March 28th. SVB Leerink downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and cut their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a "market perform" rating for the company. Finally, Leerink Partnrs downgraded shares of Amgen from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $295.30.

Amgen Stock Down 1.0 %

NASDAQ:AMGN traded down $2.72 during trading hours on Friday, hitting $267.28. The stock had a trading volume of 2,140,134 shares, compared to its average volume of 2,594,482. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The business has a 50 day simple moving average of $280.76 and a two-hundred day simple moving average of $281.55. The company has a market cap of $143.24 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 2.52 and a beta of 0.58.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen's revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter last year, the company earned $4.09 earnings per share. Analysts predict that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.37%. The ex-dividend date is Thursday, May 16th. Amgen's dividend payout ratio (DPR) is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.